CAJ | 학술논문

　　目的探讨经皮下注射超声造影剂Sonazoid检测荷瘤兔乳腺癌前哨淋巴结的可行性。方法采用组织块悬液原位注射法制作兔VX2乳腺癌模型14只，经皮下注射Sonazoid对荷瘤兔模型肿块进行超声造影检查，定位同侧腋下前哨淋巴结，并分析造影增强声像图表现特征。然后采用99Tcm硫化物核素法及皮下注射美蓝的方法定位前哨淋巴结，三种方法对比并与手术及病理结果相对照。结果经手术和病理证实的25个前哨淋巴结中，超声造影检出20个，检出率为80.00%（20/25）；99Tcm硫化物核素法检出率是76.00%（19/25），皮下注射美蓝检出率是80.00%（20/25），超声造影与另两者比较检出率相当（χ2=0.15，P＞0.05）。超声造影对判定前哨淋巴结转移与否的灵敏度、特异度和正确率分别为94.11%、66.67%和90.00%。结论经皮下注射超声造影剂Sonazoid可较好地检测出前哨淋巴结，并能发现良恶性淋巴结的不同灌注特征，可为前哨淋巴结转移提供一种新的诊断依据。
　　목적탐토경피하주사초성조영제Sonazoid검측하류토유선암전초림파결적가행성。방법채용조직괴현액원위주사법제작토VX2유선암모형14지，경피하주사Sonazoid대하류토모형종괴진행초성조영검사，정위동측액하전초림파결，병분석조영증강성상도표현특정。연후채용99Tcm류화물핵소법급피하주사미람적방법정위전초림파결，삼충방법대비병여수술급병리결과상대조。결과경수술화병리증실적25개전초림파결중，초성조영검출20개，검출솔위80.00%（20/25）；99Tcm류화물핵소법검출솔시76.00%（19/25），피하주사미람검출솔시80.00%（20/25），초성조영여령량자비교검출솔상당（χ2=0.15，P＞0.05）。초성조영대판정전초림파결전이여부적령민도、특이도화정학솔분별위94.11%、66.67%화90.00%。결론경피하주사초성조영제Sonazoid가교호지검측출전초림파결，병능발현량악성림파결적불동관주특정，가위전초림파결전이제공일충신적진단의거。
Objective To explore the feasibility for identifying and localizing the sentinel lymph nodes (SLN) of rabbit model bearing VX2 breast cancer by using contrast-enhanced ultrasound (CEUS) with subcutaneous injected agents(Son-azoid). Methods Fourteen rabbit VX2 breast cancer models were established successfully. The detection of SLN was per-formed by CEUS with subcutaneous injected Sonazoid and followed with a characteristic and quantitative analysis. The 99Tc-SC dynamic imaging and blue dye methods were performed also to detect the SLN. The results of these methods and the pathological findings were compared each other. Results There were 25 SLNs identified by surgical dissection and pathology. The detected rate of CEUS, 99Tc-SC dynamic imaging and blue dye methods were 80.00%(20/25), 76.00%(19/25) and 80.00%(20/25) respectively. There was no significant difference of the detected rate among these methods (χ2=0.15,P>0.05).The sensitivity, specificity and accuracy of CEUS for assessing the metastatic SLN were 94.l1%, 66.67% and 90.00% respectively. Conclusions CEUS can be considered as a new method to detect the lymphatic drainage pathways and SLNs in rabbits VX2 breast cancer models.